Metraipolis › archive › dc_618477332b34
Rituximab vs. cyclophosphamide in treatment-naive IMN: efficacy and renal protection in early renal impairment — Europe PMC PMID:42258058
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42258058
- DOI
- 10.1007/s10157-[numero omesso]-w
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T16:52:40.879Z
- SHA-256 of the archived text
0e1ca77d20fc569287408ce9881d568c4739c6c0b6086636f395b92dd1e7f8d4- Stable URL of this page
https://metraipolis.com/documento/dc_618477332b34
How to cite
Rituximab vs. cyclophosphamide in treatment-naive IMN: efficacy and renal protection in early renal impairment — Europe PMC PMID:42258058 — Europe PMC (en), https://europepmc.org/article/MED/42258058 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_618477332b34 (Metraipolis archive dc_618477332b34, sha256 0e1ca77d20fc569287408ce9881d568c4739c6c0b6086636f395b92dd1e7f8d4)
BibTeX
@misc{dc618477332b34,
title = {Rituximab vs. cyclophosphamide in treatment-naive IMN: efficacy and renal protection in early renal impairment — Europe PMC PMID:42258058},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42258058},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_618477332b34; sha256 0e1ca77d20fc569287408ce9881d568c4739c6c0b6086636f395b92dd1e7f8d4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42258058. Agents can read the archived copy with the MCP tool read_document.